Biotechnology
Compare Stocks
5 / 10Stock Comparison
ASBPW vs SNDL vs GRWG vs IIPR vs ACB
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Specialty Retail
REIT - Industrial
Drug Manufacturers - Specialty & Generic
ASBPW vs SNDL vs GRWG vs IIPR vs ACB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Specialty Retail | REIT - Industrial | Drug Manufacturers - Specialty & Generic |
| Market Cap | $125K | $376M | $85M | $1.62B | $195M |
| Revenue (TTM) | $2K | $937M | $162M | $263M | $361M |
| Net Income (TTM) | $-32M | $-11M | $-24M | $120M | $41M |
| Gross Margin | 45.5% | 27.2% | 26.8% | 60.3% | 62.7% |
| Operating Margin | -10314.0% | -0.8% | -15.7% | 46.7% | 13.3% |
| Forward P/E | — | — | — | 13.2x | 164.2x |
| Total Debt | $1M | $170M | $29M | $394M | $104M |
| Cash & Equiv. | $4K | $273M | $30M | $48M | $184M |
ASBPW vs SNDL vs GRWG vs IIPR vs ACB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBPW) | 100 | 25.3 | -74.7% |
| SNDL Inc. (SNDL) | 100 | 90.1 | -9.9% |
| GrowGeneration Corp. (GRWG) | 100 | 124.6 | +24.6% |
| Innovative Industri… (IIPR) | 100 | 78.7 | -21.3% |
| Aurora Cannabis Inc. (ACB) | 100 | 67.3 | -32.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBPW vs SNDL vs GRWG vs IIPR vs ACB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ASBPW lags the leaders in this set but could rank higher in a more targeted comparison.
SNDL is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.18, Low D/E 15.4%, current ratio 4.88x
- Beta 1.18, current ratio 4.88x
GRWG ranks third and is worth considering specifically for momentum.
- +25.7% vs ASBPW's -66.2%
IIPR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 9 yrs, beta 0.92, yield 13.5%
- 436.4% 10Y total return vs ASBPW's -81.9%
- Lower P/E (13.2x vs 164.2x)
- 45.6% margin vs ASBPW's -16K%
ACB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- 27.0% revenue growth vs ASBPW's -25.4%
- 5.2% ROA vs ASBPW's -13.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.0% revenue growth vs ASBPW's -25.4% | |
| Value | Lower P/E (13.2x vs 164.2x) | |
| Quality / Margins | 45.6% margin vs ASBPW's -16K% | |
| Stability / Safety | Beta 0.92 vs ASBPW's 3.15 | |
| Dividends | 13.5% yield; 9-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +25.7% vs ASBPW's -66.2% | |
| Efficiency (ROA) | 5.2% ROA vs ASBPW's -13.2% |
ASBPW vs SNDL vs GRWG vs IIPR vs ACB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
ASBPW vs SNDL vs GRWG vs IIPR vs ACB — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IIPR leads in 3 of 6 categories
ASBPW leads 0 • SNDL leads 0 • GRWG leads 0 • ACB leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IIPR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SNDL is the larger business by revenue, generating $937M annually — 482943.3x ASBPW's $1,941. IIPR is the more profitable business, keeping 45.6% of every revenue dollar as net income compared to ASBPW's -16351.8%. On growth, ACB holds the edge at +6.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1,941 | $937M | $162M | $263M | $361M |
| EBITDAEarnings before interest/tax | -$28M | $49M | -$14M | $197M | $71M |
| Net IncomeAfter-tax profit | -$32M | -$11M | -$24M | $120M | $41M |
| Free Cash FlowCash after capex | -$4M | $53M | -$10M | $144M | -$31M |
| Gross MarginGross profit ÷ Revenue | +45.5% | +27.2% | +26.8% | +60.3% | +62.7% |
| Operating MarginEBIT ÷ Revenue | -10314.0% | -0.8% | -15.7% | +46.7% | +13.3% |
| Net MarginNet income ÷ Revenue | -16351.8% | -1.2% | -14.9% | +45.6% | +11.2% |
| FCF MarginFCF ÷ Revenue | -1811.5% | +5.6% | -6.2% | +54.7% | -8.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -4.4% | +1.0% | -3.8% | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +46.0% | +32.8% | +69.2% | -1.0% | -94.5% |
Valuation Metrics
Evenly matched — SNDL and ACB each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 14.4x trailing earnings, IIPR trades at a 91% valuation discount to ACB's 164.2x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than IIPR's 9.9x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $125,312 | $376M | $85M | $1.6B | $195M |
| Enterprise ValueMkt cap + debt − cash | $1M | $301M | $84M | $2.0B | $136M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -32.97x | -3.55x | 14.40x | 164.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 13.17x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 3.85x | — |
| EV / EBITDAEnterprise value multiple | — | 7.91x | — | 9.91x | 6.73x |
| Price / SalesMarket cap ÷ Revenue | — | 0.54x | 0.53x | 6.08x | 0.77x |
| Price / BookPrice ÷ Book value/share | — | 0.46x | 0.87x | 0.87x | 0.43x |
| Price / FCFMarket cap ÷ FCF | — | 8.83x | — | 9.26x | — |
Profitability & Efficiency
Evenly matched — IIPR and ACB each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-23 for GRWG. SNDL carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to GRWG's 0.30x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs ASBPW's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -1.0% | -22.9% | +6.4% | +7.2% |
| ROA (TTM)Return on assets | -13.2% | -0.8% | -15.2% | +5.1% | +5.2% |
| ROICReturn on invested capital | — | -0.3% | -16.9% | +4.3% | +0.7% |
| ROCEReturn on capital employed | — | -0.4% | -18.8% | +5.8% | +0.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 0.15x | 0.30x | 0.21x | 0.17x |
| Net DebtTotal debt minus cash | $1M | -$102M | -$929,000 | $346M | -$80M |
| Cash & Equiv.Liquid assets | $3,633 | $273M | $30M | $48M | $184M |
| Total DebtShort + long-term debt | $1M | $170M | $29M | $394M | $104M |
| Interest CoverageEBIT ÷ Interest expense | -10.51x | -1.16x | — | 6.67x | 6.27x |
Total Returns (Dividends Reinvested)
IIPR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IIPR five years ago would be worth $4,999 today (with dividends reinvested), compared to $330 for GRWG. Over the past 12 months, GRWG leads with a +25.7% total return vs ASBPW's -66.2%. The 3-year compound annual growth rate (CAGR) favors IIPR at 4.5% vs ASBPW's -43.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -18.3% | -16.7% | -7.8% | +18.3% | -21.0% |
| 1-Year ReturnPast 12 months | -66.2% | +11.5% | +25.7% | +20.3% | -25.3% |
| 3-Year ReturnCumulative with dividends | -81.9% | -16.2% | -62.0% | +14.1% | -47.2% |
| 5-Year ReturnCumulative with dividends | -81.9% | -81.1% | -96.7% | -50.0% | -96.1% |
| 10-Year ReturnCumulative with dividends | -81.9% | -98.3% | -75.7% | +436.4% | -92.0% |
| CAGR (3Y)Annualised 3-year return | -43.4% | -5.7% | -27.6% | +4.5% | -19.2% |
Risk & Volatility
IIPR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IIPR is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than ASBPW's 3.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IIPR currently trades 92.2% from its 52-week high vs ASBPW's 16.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.15x | 1.18x | 1.27x | 0.92x | 1.81x |
| 52-Week HighHighest price in past year | $0.09 | $2.89 | $2.40 | $61.40 | $6.67 |
| 52-Week LowLowest price in past year | $0.01 | $1.15 | $0.87 | $44.58 | $3.07 |
| % of 52W HighCurrent price vs 52-week peak | +16.9% | +50.2% | +59.2% | +92.2% | +51.4% |
| RSI (14)Momentum oscillator 0–100 | 52.4 | 49.7 | 63.2 | 59.3 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 23K | 1.9M | 476K | 303K | 979K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SNDL as "Hold", IIPR as "Hold", ACB as "Hold". Consensus price targets imply 172.4% upside for SNDL (target: $4) vs -22.3% for IIPR (target: $44). IIPR is the only dividend payer here at 13.46% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | — | Hold | Hold |
| Price TargetConsensus 12-month target | — | $3.95 | — | $44.00 | $5.92 |
| # AnalystsCovering analysts | — | 6 | — | 11 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +13.5% | — |
| Dividend StreakConsecutive years of raises | — | — | — | 9 | — |
| Dividend / ShareAnnual DPS | — | — | — | $7.62 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.0% | 0.0% | +1.2% | 0.0% |
IIPR leads in 3 of 6 categories — strongest in Income & Cash Flow and Total Returns. 2 categories are tied.
ASBPW vs SNDL vs GRWG vs IIPR vs ACB: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ASBPW or SNDL or GRWG or IIPR or ACB a better buy right now?
For growth investors, Aurora Cannabis Inc.
(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus -14. 4% for GrowGeneration Corp. (GRWG). Innovative Industrial Properties, Inc. (IIPR) offers the better valuation at 14. 4x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate SNDL Inc. (SNDL) a "Hold" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ASBPW or SNDL or GRWG or IIPR or ACB?
On trailing P/E, Innovative Industrial Properties, Inc.
(IIPR) is the cheapest at 14. 4x versus Aurora Cannabis Inc. at 164. 2x.
03Which is the better long-term investment — ASBPW or SNDL or GRWG or IIPR or ACB?
Over the past 5 years, Innovative Industrial Properties, Inc.
(IIPR) delivered a total return of -50. 0%, compared to -96. 7% for GrowGeneration Corp. (GRWG). Over 10 years, the gap is even starker: IIPR returned +436. 4% versus SNDL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ASBPW or SNDL or GRWG or IIPR or ACB?
By beta (market sensitivity over 5 years), Innovative Industrial Properties, Inc.
(IIPR) is the lower-risk stock at 0. 92β versus Aspire Biopharma Holdings, Inc. 's 3. 15β — meaning ASBPW is approximately 244% more volatile than IIPR relative to the S&P 500. On balance sheet safety, SNDL Inc. (SNDL) carries a lower debt/equity ratio of 15% versus 30% for GrowGeneration Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — ASBPW or SNDL or GRWG or IIPR or ACB?
By revenue growth (latest reported year), Aurora Cannabis Inc.
(ACB) is pulling ahead at 27. 0% versus -14. 4% for GrowGeneration Corp. (GRWG). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -381. 5% for Aspire Biopharma Holdings, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ASBPW or SNDL or GRWG or IIPR or ACB?
Innovative Industrial Properties, Inc.
(IIPR) is the more profitable company, earning 43. 0% net margin versus -16351. 8% for Aspire Biopharma Holdings, Inc. — meaning it keeps 43. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIPR leads at 46. 7% versus -10314. 0% for ASBPW. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ASBPW or SNDL or GRWG or IIPR or ACB more undervalued right now?
Analyst consensus price targets imply the most upside for SNDL: 172.
4% to $3. 95.
08Which pays a better dividend — ASBPW or SNDL or GRWG or IIPR or ACB?
In this comparison, IIPR (13.
5% yield) pays a dividend. ASBPW, SNDL, GRWG, ACB do not pay a meaningful dividend and should not be held primarily for income.
09Is ASBPW or SNDL or GRWG or IIPR or ACB better for a retirement portfolio?
For long-horizon retirement investors, Innovative Industrial Properties, Inc.
(IIPR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), 13. 5% yield, +436. 4% 10Y return). Aspire Biopharma Holdings, Inc. (ASBPW) carries a higher beta of 3. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IIPR: +436. 4%, ASBPW: -81. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ASBPW and SNDL and GRWG and IIPR and ACB?
These companies operate in different sectors (ASBPW (Healthcare) and SNDL (Healthcare) and GRWG (Consumer Cyclical) and IIPR (Real Estate) and ACB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ASBPW is a small-cap quality compounder stock; SNDL is a small-cap quality compounder stock; GRWG is a small-cap quality compounder stock; IIPR is a small-cap deep-value stock; ACB is a small-cap high-growth stock. IIPR pays a dividend while ASBPW, SNDL, GRWG, ACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.